Jump Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jump Financial’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92M	Buy	51,400 +35,400	+221%	+$1.32M	0.02%	921
2026 Q1	$581K	Buy	+16,000	New	+$715K	0.01%	1169
2025 Q3	–	Sell	-8,780	Closed	-$253K	–	1858
2025 Q2	$253K	Sell	8,780 -10,020	-53%	-$309K	﹤0.01%	1502
2025 Q1	$631K	Buy	+18,800	New	+$702K	0.01%	990
2024 Q1	–	Sell	-27,083	Closed	-$964K	–	1954
2023 Q4	$964K	Sell	27,083 -20,393	-43%	-$625K	0.03%	741
2023 Q3	$1.41M	Buy	+47,476	New	+$978K	0.05%	507
2022 Q4	–	Sell	-28,500	Closed	-$560K	–	1642
2022 Q3	$560K	Buy	+28,500	New	+$581K	0.02%	845

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jump Financial's CRNX Position: Q2 2026 in Review

Jump Financial increased its Crinetics Pharmaceuticals (CRNX) stake by 221% in Q2 2026, buying an estimated $1.32M and bringing the position to 51,400 shares worth $1.92M. The position accounts for 0.02% of the portfolio, ranked #921.

Jump Financial first reported a position in CRNX in Q3 2022 and has held it in 7 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Jump Financial held 51,400 shares of Crinetics Pharmaceuticals worth $1.92M as of Q2 2026.
Jump Financial bought 35,400 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
Crinetics Pharmaceuticals made up 0.02% of Jump Financial's portfolio in Q2 2026, its #921 holding.
Jump Financial first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.